MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pemetrexed (Alimta)

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Oncoimmunology 2017 July [Link] Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC Abstract Background: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies. We have previously shown PD-L1 expression in 40% of malignant mesothelioma (MM); however, the temporal and spatial heterogeneity of its […]

Comments Off on Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

Investigational New Drugs 2017 November 8 [Epub ahead of print] [Link] Link De A, Jacobson BA, Peterson MS, Jay-Dixon J, Kratzke MG, Sadiq AA, Patel MR, Kratzke RA Abstract Deregulation of cap-dependent translation has been implicated in the malignant transformation of numerous human tissues. 4EGI-1, a novel small-molecule inhibitor of cap-dependent translation, disrupts formation of […]

Comments Off on 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

Cancer Chemotherapy and Pharmacology 2017 November 10 [Epub ahead of print] [Link] Matherly LH, Hou Z, Gangjee A Abstract This review considers the “promise” of exploiting the proton-coupled folate transporter (PCFT) for selective therapeutic targeting of cancer. PCFT was discovered in 2006 and was identified as the principal folate transporter involved in the intestinal absorption […]

Comments Off on The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Future Oncology 2017 September [Epub ahead of print] [Link] Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, […]

Comments Off on A review of bevacizumab in the treatment of malignant pleural mesothelioma

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.

Journal of Korean Medical Science 2017 November [Link] Kim JS, Lim SY, Hwang J, Kang EJ, Choi YJ Abstract Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural […]

Comments Off on A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.

Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Cancer Medicine 2017 September [Epub ahead of print] [Link] Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A Abstract The aim of this study was to evaluate the role of metabolic […]

Comments Off on Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.

Annals of Oncology 2017 September [Epub ahead of print] [Link] Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struijs EA, Perrino M, Jansen G, Matherly LH, Peters GJ Abstract BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed-treatment of mesothelioma, however additional chemoresistance mechanisms […]

Comments Off on Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase […]

Comments Off on Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

Asian Pacific Journal of Cancer Prevention 2017 August [Link] Rahouma M, Aziz H, Ghaly G, Kamel M, Loai I, Mohamed A Abstract Purpose: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. Methods: We retrospectively reviewed […]

Comments Off on Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy

ESMO 2017 April [Link] Dolly SO, Migali C, Tunariu N, Della-Pepa C, Khakoo S, Hazell S, de Bono JS, Kaye SB, Banerjee S Abstract Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, […]

Comments Off on Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy